このエントリーをはてなブックマークに追加
ID 38084
本文ファイル
著者
Mtasiwa, Deodatus M.
Imamura, Nobutaka
Inada, Tominari
Takimoto, Yasuo
Okada, Kosuke
Nanba, Koji
Asaoku, Hideki
Kuramoto, Atsushi
キーワード
Immunophenotype
Histology
Clinical stage
Prognosis of NHL
NDC
医学
抄録(英)
The relationship between immunophenotype, histopathology and clinical stage in influencing prognosis was evaluated in 99 cases of non-Hodgkin's lymphoma (NHL). All cases were histopathologically classified according to the system of the international conference on working formulation (WF), immunologically analysed by flow cytometry with a panel of monoclonal antibodies and clinically staged by the Ann Arbor scheme. Eighty eight percent of T- and 87.7% of B-phenotype NHLs respectively received combination chemotherapies with or without radiotherapy. Early stages I and II showed higher response rates (86% for T- and B-NHL) compared to the advanced ones III and IV (58% for T-NHL and 65% for the B-NHLs), p<0.05. Higher overall survival rates were observed in low and intermediate grade NHLs, p < 0.05. The early stages further showed relatively higher survival rates in T- than in B-phenotype of intermediate grade NHL. Low grade NHL had the highest survival rates in both early and advanced stages, whereas the survival rate was the lowest in high grade NHL irrespective of the clinical stages. Immunophenotype, pathological grade and clinical stage jointly displayed varied predictive values in the prognosis of NHL. Since the present prognostic models are based on histological and staging criteria only, the results suggest that, phenotype should be included in the classification systems or prognostic models for the NHLs, thus facilitating the establishment of effective lineage specific therapies.
掲載誌名
Hiroshima Journal of Medical Sciences
39巻
4号
開始ページ
95
終了ページ
102
出版年月日
1990-12
出版者
Hiroshima University Medical Press
ISSN
0018-2052
NCID
PubMedID
言語
英語
NII資源タイプ
紀要論文
広大資料タイプ
学内刊行物(紀要等)
DCMIタイプ
text
フォーマット
application/pdf
著者版フラグ
publisher
部局名
原爆放射線医科学研究所
病院
総合科学研究科
医歯薬学総合研究科
他の一覧